Customized Demand Case of Photoinitiator 184 with Strict Limits: Phenol ≤3ppm & Single Organic Impurities Such as Cyclohexanone ≤5ppm

As a new foreign trade service provider driven by technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply photoinitiator 184 sourced from multiple well-known original manufacturers. Integrating R&D capabilities with foreign trade operations, HiSiaddi has repeatedly resolved customized product demands for photoinitiator 184 through technological transformation cooperation with factories and precise insight into market demands. Below is a case demonstrating how HiSiaddi addressed customized requirements for photoinitiator 184.

Contact HiSiaddi customer service if you need customized service support.

I. Basic Client Profile (High-end Overseas End User, Non-intermediary or Low-end Processor)

Purchaser: FINMED OY, a listed Finnish medical packaging group headquartered in Finland. It specializes in sterile medical infusion bags, pharmaceutical composite films, UV-curable coatings for PET rigid sheets of single-use medical devices. Its products are supplied to multiple public hospitals across Northern Europe and world-famous pharmaceutical enterprises, complying with EU EU10/2011 regulations for food and pharmaceutical contact materials, REACH, USP Pharmacopoeia, and Nordic MKS standards for medical material control.

The client previously purchased Omnirad 184, the original product from IGM, with a stable annual procurement volume of 98 tons. Faced with continuous price hikes by European manufacturers and overseas plant maintenance, the import delivery cycle was extended to 65 days. Hence, the client initiated localized customized alternative sourcing from China.

The client independently contacted three leading domestic photoinitiator manufacturers: Jiuri New Materials, Strong New Materials, and Yangfan New Materials. Their mass production lines adopt general industrial-grade processes targeting common plastic and ink applications. Medical-grade products require optimized synthetic catalysts, multi-stage negative pressure rectification, closed low-temperature crystallization, and full-process dust-free light-shielded production. Line renovation entails high investment and occupies dedicated production capacity, so all manufacturers prioritized stock general-grade products and refused to launch separate customized production runs.

After five rounds of sample testing, widespread issues emerged including excessive phenol residues, over-limit trace cyclohexanone by-products, precipitation at high temperatures, and coating odor, halting the pilot production of medical formulations. The client entrusted HiSiaddi with indicator decomposition, process customization, full-cycle validation from lab trials to pilot and mass production, and complete EU compliance implementation.

II. Rigid Technical Specifications for Custom Medical-Grade 184 (Far Superior to National Industrial Grade Standards)

Conventional domestic industrial-grade 184 specifications: Purity ≥98.5%, phenol ≤50ppm, cyclohexanone by-products ≤200ppm. Strict customized standards for Finnish medical applications:

1. Effective main component purity ≥99.75%; phenol ≤3ppm, single organic impurities including cyclohexanone ≤5ppm, total impurities ≤12ppm;

2. Heavy metals (Pb, As, Cd, Hg) individually <10ppb, halogen-free, compliant with medical packaging RoHS control;

3. APHA color ≤15, no pungent odor, no small molecule precipitation after 121°C high-temperature steaming;

4. Low volatility, no migration of cured coatings, meeting the limit of simulated pharmaceutical packaging solvent migration <0.01mg/kg;

5. Packaging: 25kg light-proof iron drums lined with aluminum foil, nitrogen-sealed inside drums to prevent oxidation and deterioration during storage and transportation;

6. Full supporting documents per batch: HPLC full spectrum, English SGS Certificate of Analysis (COA), pharmaceutical migration test report, and REACH compliance documents.

III. Four Major Customization Bottlenecks Encountered by the Client When Directly Cooperating with Factories

Bottleneck 1: Fixed General Mass Production Processes, Manufacturers Unwilling to Conduct Special Technical Renovations

Domestic industrial production of 184 adopts low-cost catalytic synthesis plus single-tower rectification. Production of high-purity medical customized products requires ultra-high-purity starting materials, two additional light-component removal rectification sections, and a closed low-temperature crystallization workshop. Renovation costs are high, and customized orders account for a low proportion of production capacity, resulting in manufacturers’ reluctance to implement technical upgrades.

Bottleneck 2: Similar Boiling Points of By-products Prevent Deep Impurity Removal via Conventional Rectification

Synthesis by-products of 184 (cyclohexanone, phenol) share close boiling points with the main product. Ordinary rectification can only achieve rough separation and cannot remove trace impurities down to ppm levels. Excessive by-products directly cause precipitation and odor exceeding limits in medical films after high-temperature treatment.

Bottleneck 3: Qualified Lab Samples with Unstable Mass Production Indicators

Manufacturers can temporarily purify lab samples to meet standards, yet mass production suffers fluctuating indicators due to inconsistent raw material purity, temperature control, and crystallization rates during large-scale feeding. Batch-to-batch fluctuations in impurities and color fail to meet the stability requirements of continuous medical production.

Bottleneck 4: Lack of Special EU Compliance Documents for Medical Applications

Factories can only provide national standard quality inspection certificates, lacking EU10/2011 pharmaceutical migration reports, USP compliance statements, and Nordic MKS compliance documents, which block IQC warehouse admission audits by Finnish pharmaceutical enterprises.

IV. Four-Stage Full-Cycle Customization Implementation by HiSiaddi

Stage 1: Screen Production Bases and Optimize Synthetic & Refining Processes Targetedly

HiSiaddi screened domestic fine chemical manufacturers equipped with high-purity alcohol-ketone catalytic synthesis, three-stage negative pressure rectification, and dust-free light-shielded crystallization workshops, and collaborated with factory R&D teams to upgrade processes directionally:

1. Adopt ultra-high-purity raw materials and special selective catalysts to reduce generation of phenol and cyclohexanone by-products at the source;

2. Build an independent dedicated production line with three-stage stepped negative pressure rectification to accurately separate light and heavy fractions section by section, equipped with special adsorption fillers to deeply remove trace organic impurities;

3. Add an ion exchange refining process to eliminate trace heavy metals and halogen ions; finished products are fully stored in nitrogen-sealed, light-shielded environments.

Stage 2: Gradient Sample & Pilot Verification with Formulation Adjustment for Finnish Clients

1. 6kg lab trial: Finalize full process parameters, send samples to CNAS third-party labs for full-item testing. After passing inspection, airfreight samples to the client’s Finnish R&D center for medical film formulation debugging, and fine-tune rectification parameters based on curing efficiency and steaming precipitation test data;

2. 350kg continuous pilot production: Conduct parallel production of 3 batches, subject samples to 90-day high-low temperature accelerated stability storage tests, and finalize standardized SOP covering feeding ratio, reaction temperature, vacuum degree, and fraction interception;

3. Assign HiSiaddi process engineers to conduct full-process on-site inspections, sampling products at every working procedure from raw material incoming to filling.

Stage 3: Medical-Specific Sealed Packaging & Complete EU Pharmaceutical Compliance Documents

1. Custom light-proof iron drums lined with aluminum foil: Drums are high-temperature dried and nitrogen-displaced and sealed before filling to isolate air oxidation and moisture absorption;

2. HiSiaddi coordinates compilation of complete document archives: HPLC full-component spectra, batch stability reports, SGS pharmaceutical migration test reports; compile English-Finnish bilingual SDS, medical-grade compliance statements, and MKS Nordic raw material compliance certificates in accordance with REACH and CLP regulations.

Stage 4: Reserve Exclusive Production Capacity and Coordinate Production Scheduling & Customs Clearance

Negotiate with manufacturers to reserve dedicated production lines for medical-grade 184, isolating production from industrial-grade batches to avoid cross-contamination. Schedule production monthly based on order volume, complete hazardous goods classification, commodity inspection and customs clearance, and ship goods to Helsinki Port, Finland on schedule.

V. Implementation Outcomes

1. The first trial order of 26 tons cleared customs and entered the warehouse smoothly. The client manufactured pharmaceutical composite films on production lines, with all high-temperature steaming, migration, and irritation tests matching the original IGM products. Finished products successfully passed Finnish Food and Drug Administration filing and entered mass production for Northern European hospital supply chains;

2. Procurement costs of customized domestic raw materials decreased by 29.1% compared with imported original products, and delivery cycles were shortened from 65 days to 22–28 days. A 98-ton annual procurement framework for medical-grade 184 was finalized, delivered evenly in 11 batches;

3. The client entrusted HiSiaddi with exclusive development and customization of upgraded low-migration 184 grades for its subsequent new biodegradable pharmaceutical packaging UV projects.

VI. Case Summary

1. Mainstream domestic production capacity for 184 focuses on ink and general plastic industrial grades. Medical ultra-low impurity customized products require dedicated production line investment, making it difficult for manufacturers to independently fulfill non-standard customization demands from overseas high-end clients;

2. Core value of HiSiaddi: Bridge the full chain including medical indicator decomposition, factory technical renovation, multi-stage sample verification, special pharmaceutical testing, and full EU compliance, eliminating technical and regulatory barriers between manufacturers and European high-end medical clients;

3. Priority purchasing criteria for European medical packaging: Low impurities, zero migration, complete compliance > unit price. Customized technical support and matching compliance services are the key to domestic substitution and long-term cooperation with high-end clients.

Contact HiSiaddi customer service if you require customized service support.